KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Moderna's Cash & Equivalents fell 31.14% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 31.14%. This contributed to the annual value of $1.9 billion for FY2024, which is 33.71% down from last year.
  • According to the latest figures from Q3 2025, Moderna's Cash & Equivalents is $1.1 billion, which was down 11.49% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Moderna's Cash & Equivalents registered a high of $6.8 billion during Q4 2021, and its lowest value of $1.1 billion during Q3 2025.
  • For the 3-year period, Moderna's Cash & Equivalents averaged around $2.3 billion, with its median value being $2.1 billion (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 1,288.27% in 2021, then tumbled by 53.20% in 2022.
  • Moderna's Cash & Equivalents (Quarterly) stood at $6.8 billion in 2021, then slumped by 53.20% to $3.2 billion in 2022, then decreased by 9.30% to $2.9 billion in 2023, then plummeted by 33.71% to $1.9 billion in 2024, then plummeted by 31.14% to $1.1 billion in 2025.
  • Its Cash & Equivalents was $1.1 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.6 billion in Q1 2025.